质谱与二代测序在白血病微小残留病及低水平突变检测中的多重技术对比
该综述聚焦白血病管理中低水平疾病负担检测需求,比较质谱技术与二代测序在可测量残留病(MRD)及低水平突变检测中的方法学。两者均可同时 interrogate 多个基因,弥补多数方法仅检测单克隆或单突变的不足;文中探讨了各自优势、局限、应用证据及未来MRD检测策略。
要点
- 质谱与二代测序均可同时检测多个基因,提供更完整基因组谱。
- 多数MRD检测方法仅能检测单克隆或单突变,存在局限。
- 两种技术各有优势与局限,需结合证据选择并规划未来策略。
核心结论
- 质谱与二代测序可同时检测多个基因,比仅检测单克隆或单突变的方法提供更完整基因组信息。
研究设计与样本
- 本文为综述,探讨质谱与二代测序两种技术在白血病MRD及低水平突变检测中的方法学。
主要发现
- 多数MRD检测方法仅允许检测单一克隆或突变。
- 质谱与二代测序可同时 interrogate 多个基因,促进更完整基因组谱。
临床怎么用
- 在白血病管理中可考虑用质谱或二代测序进行多重MRD及低水平突变检测。
- 选择技术时需权衡各自优势与局限,并参考已有应用证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With the focus of leukaemia management shifting to the implications of low-level disease burden, increasing attention is being paid on the development of highly sensitive methodologies required for detection. There are various techniques capable of identification of measurable residual disease (MRD) either evidencing as relevant mutation detection [e.g. nucleophosmin 1 (NPM1) mutation] or trace levels of leukaemic clonal populations. The vast majority of these methods only permit detection of a single clone or mutation. However, mass spectrometry and next-generation sequencing enable the interrogation of multiple genes simultaneously, facilitating a more complete genomic profile. In the present review, we explore the methodologies of both techniques in conjunction with the important advantages and limitations associated with each assay. We also highlight the evidence and the various instances where either technique has been used and propose future strategies for MRD detection.
引用
- Shanmuganathan N, Branford S. Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing. Br J Haematol. 2021. PMID: 34124782. doi:10.1111/bjh.17623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。